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CASE REPORT | PANCREAS
Metastatic Pancreatic Adenocarcinoma During Pregnancy
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ABSTRACT
We present a rare case of metastatic pancreatic adenocarcinoma diagnosed antepartum. A high index of suspi-
cion must be maintained to diagnose pancreatic cancer during pregnancy. We recommend a thorough history
and physical and aggressive pursuit of sensitive imaging in patients with persistent symptoms. If pancreatic ade-
nocarcinoma is diagnosed, a multidisciplinary approach that focuses on patient goals should be undertaken. The
effect of pregnancy on tumor growth rates is unknown.
INTRODUCTION
Pancreatic cancer is the third leading cause of cancer-related death in the United States.1 Diagnosis of pancreatic
adenocarcinoma antepartum is, however, exceedingly rare, with 13 cases published to date.2-14 Of the previously
reported cases, the mean maternal age at diagnosis is 35.8 years (range, 25–43 years).2-14 Nine of the 13 patients
were diagnosed during their second trimester of pregnancy, with the remaining patients presenting in the third tri-
mester. No cases were diagnosed in the first trimester of pregnancy.2-14 Only 5 of the 13 cases were amenable to
resection, and in those cases pancreaticoduodenectomy was performed anywhere from 17 weeks gestation to post-
partum.2-14 Eight cases reported patient death within 1 year of diagnosis.2-14 The longest documented survival was 16
months after diagnosis.2-14 Fetal outcome was largely positive; one case noted elective termination and there was
one spontaneous fetal death, but all other cases reported healthy pregnancies or infants subsequent to
diagnosis.2-14
CASE REPORT
A 34-year-old gravida 1 para 0 woman with past medical history of multiple sclerosis and cholecystectomy
presented at 26 weeks gestation with severe abdominal pain and failure to gain weight appropriately in
pregnancy. Her family history was remarkable for pancreatic cancer in her mother, who died at age 47. She
did not smoke or drink alcohol. Admission labs were notable for aspartate aminotransferase (AST) 68 U/L,
alanine aminotransferase (ALT) 100 U/L, alkaline phosphatase (ALP) 227 U/L, total bilirubin 0.3 mg/dL, lipase
364 U/L, and bile acids 25 mmol/L. Ultrasound showed dilatation of both the common bile duct (CBD) (7.4
mm) and pancreatic duct (9.6 mm). Subsequent magnetic resonance cholangiopancreatography (MRCP) dem-
onstrated a space-occupying lesion in the pancreatic head with a mildly dilated CBD (Figure 1). The differen-
tial diagnosis of the lesion included an inflammatory mass due to acute pancreatitis versus neoplasm. Her
family history was her only known risk factor for pancreatic cancer. Although her findings were concerning,
endoscopic ultrasound was deferred due to the patient’s preference. She was treated for acute pancreatitis
with inflammatory mass with pain control and pancreatic enzyme replacement (pancreatic lipase, 500 U/kg
per meal) in an attempt to ameliorate her pain and address any component of pancreatic insufficiency that
may have contributed to her weight loss.
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She returned 1 week later with persistent abdominal pain,
weight loss, and emesis. Her liver-associated enzymes were
similar to her prior admission values with AST 65 U/L, ALT 76
U/L, ALP 186 U/L, and total bilirubin 0.4 mg/dL. Her AST,
ALT, and ALP remained stable, whereas her total bilirubin
rose to 3.0 mg/dL. Given the patient’s preference to avoid
invasive procedures, a second MRCP was performed to
reevaluate the previously identified mass in light of her
increased bilirubin. Repeat MRCP was again concerning for a
pancreatic head mass and increased dilatation of her CBD
(Figure 2). Endoscopic ultrasound was performed at 32 weeks
gestation and demonstrated a 3.8 x 2.3 cm pancreatic head
mass encasing the superior mesenteric vein with celiac and
peripancreatic lymphadenopathy (Figure 3). There were no
endoscopic luminal findings to explain her emesis. Pathology
on fine-needle aspiration of the pancreatic head mass con-
firmed pancreatic adenocarcinoma (Figure 4). Given her fam-
ily history and young age at diagnosis, we recommended she
undergo genetic counseling. CA 19-9 was 1 U/mL.
C-section was performed 2 days after diagnosis, and a healthy
male infant was delivered. Pfannestiel incision allowed direct
visualization of pancreatic head mass. The mass was large and
fixed with local spread and palpable liver lesions grossly con-
sistent with metastases. The patient became jaundiced, and
her liver-associated enzymes showed worsening cholestasis
with AST 166 U/L, ALT 171 U/L, ALP 1 102 U/L, and total biliru-
bin 13.6 mg/dL. A palliative biliary stent was placed for her
worsening jaundice, and her bilirubin trended down. The
patient opted for supportive care after her delivery.
Figure 1. T2-Weighted abdominal magnetic resonance imaging from ini-
tial presentation at 26 weeks. (A) Axial view showing a space-occupying
lesion in the head of the pancreas (arrow) with ill-defined margins and
involvement of the superior mesenteric vein. (B) Coronal view demon-
strating a pancreatic head lesion (white arrow) and surrounding edema
with mild dilatation of the CBD (striped arrow) and visualization of gravid
uterus (yellow arrow).
Figure 2. T2-Weighted abdominal magnetic resonance imaging from
presentation at 30 weeks. (A) Axial view showing pancreatic head mass
(arrow). (B) Coronal view showing gravid uterus (yellow arrow), pancre-
atic head mass (white arrow), significantly increased dilatation of the
CBD (striped arrow), and an incompletely characterized hyperintense
liver lesion (dotted arrow) concerning for metastasis.
Figure 3. Endoscopic ultrasound of the pancreatic head mass (white
arrow) and portal vein demonstrating enlarged peripancreatic lymph
node (black arrow).
Figure 4. Cytology from fine-needle aspiration of the pancreatic head
mass confirming adenocarcinoma. Typical glandular type cells occurring
(A) in 3-dimensional cohesive groups and (B–E) singly. These markedly
atypical cells are enlarged with overlapping nuclei, chromatin clearing
and clumping, increased nuclear to cytoplasmic ratio, and irregular nu-
clear borders with focally vacuolated cytoplasm. Papanicolaou stain, 50x
magnification.
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Unfortunately, she died 4 months after her tissue diagnosis.
At most recent follow-up, her son was healthy with reportedly
normal development at 16 months.
DISCUSSION
Our case exemplifies the challenges of diagnosis, treatment,
and prognosis of pancreatic cancer in the pregnant patient.
Early diagnosis is critically important in these patients as it
affects survival and candidacy for surgery. Diagnosis is chal-
lenging in the gravid patient, however, as the symptoms
of pancreatic cancer—abdominal discomfort, nausea, and
vomiting—mimic those of normal pregnancy. Pregnancy
masks red flags like unintentional weight loss and abdominal
masses and decreases the sensitivity of noninvasive imaging
modalities. We recommend a careful history and physical
examination that attends to risk factors for cancer, including
family history and tobacco use. Any pregnant patient with
persistent abdominal symptoms despite supportive care
should be screened with imaging modalities. Patients often
present with persistent symptoms and lab abnormalities that
are not proportional to initial imaging findings. This indicates
that a high index of suspicion for occult malignancy is needed.
Although not typically used as a screening tool, CA 19-9 has
the potential to be useful as a noninvasive test in gravid
patients; it was elevated in 6 cases in the literature, though
not in our patient.2-14
Once the diagnosis has been made, questions regarding tim-
ing and type of therapy arise. Unfortunately, for patients like
ours with locally advanced or metastatic disease, surgical
intervention does not improve survival. Palliative chemother-
apy and/or supportive care may be offered. For patients who
present with resectable disease, surgical intervention with
pancreaticoduodenectomy has survival benefit. Five antepar-
tum cases in the literature presented with resectable disease.
Three broad options are available to these patients: immedi-
ate surgical intervention, delay of surgery until postpartum
state, or surgery at the earliest age of high fetal viability,
approximately 28 weeks.9 The first option offers the highest
risk to the fetus, the second confers the greatest risk to the
mother, and the third attempts to balance risk of both mother
and fetus, potentially at the expense of both.
Ultimately, a multidisciplinary approach among high-risk ob-
stetrics, surgery, gastroenterology, and the patient herself
will inform the decision of timing of intervention in these
cases. From a safety perspective, the second trimester is
thought to be the optimal time for surgical intervention as
the risk of spontaneous termination is high in the first trimes-
ter while access to the pancreas may be limited by the size
of the uterus in the third trimester.15
Prognosis plays a role in therapeutic decision-making as well.
Given the paucity of cases available, it is not known if there is
a difference in the natural history of pancreatic cancer in
pregnant versus non-pregnant patients. There has been spec-
ulation that the immunosuppression associated with preg-
nancy could increase the aggressiveness of some tumors,
and pancreatic cancers have estrogen and progesterone
receptors that could be affected by the gravid state.16
Immunohistochemistry was not performed on our patient’s
tissue to identify the absence or presence of estrogen or pro-
gesterone receptors, but this could be an option for future
similar cases that may prove informative when making man-
agement decisions. As noted above, evaluation of the cases
reported thus far in the literature shows that the majority of
cases are not resectable at diagnosis, and, of the 5 cases in
which the mother survived, only one provided data for longer
than 1 year.
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